Literature DB >> 16964477

[Current recommendations for the use of SCIT and SLIT].

H Lee1, J Kleine-Tebbe, T Zuberbier, M Worm.   

Abstract

Allergen specific immunotherapy (SIT) is the only potentially curative treatment of IgE mediated allergic diseases. To ensure its effective use, many requirements must be met before and during therapy. Before starting immunotherapy, informed consent should be obtained, along with the consideration of the indications and contraindications. SIT should be prescribed and administered only by physicians with experience in allergic disease who are qualified to manage severe anaphylactic reactions. The clinical symptoms and the age of the patients determine the route of application, choice of allergen extracts and the duration of treatment. Numerous products and protocols facilitate an individualised therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964477     DOI: 10.1007/s00105-006-1204-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  9 in total

Review 1.  Sublingual immunotherapy.

Authors:  Lucie Heinzerling; Margitta Worm; Karl-Christian Bergmann; Torsten Zuberbier
Journal:  J Dtsch Dermatol Ges       Date:  2006-05       Impact factor: 5.584

2.  Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy.

Authors:  H Lee; C Roediger; A Bauer; T Zuberbier; M Worm
Journal:  Allergy       Date:  2006-10       Impact factor: 13.146

Review 3.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

4.  Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial.

Authors:  S M Walker; G B Pajno; M T Lima; D R Wilson; S R Durham
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

Review 5.  [Specific immunotherapy. Hyposensitization with allergens].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

6.  Side-effects of allergen-specific immunotherapy: a prospective multi-centre study.

Authors:  L Winther; J Arnved; H-J Malling; H Nolte; H Mosbech
Journal:  Clin Exp Allergy       Date:  2006-03       Impact factor: 5.018

7.  Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.

Authors:  Graham Roberts; Catriona Hurley; Victor Turcanu; Gideon Lack
Journal:  J Allergy Clin Immunol       Date:  2006-02       Impact factor: 10.793

8.  Clinical and entomological factors influence the outcome of sting challenge studies.

Authors:  David B K Golden; Nancy L Breisch; Robert G Hamilton; Miles W Guralnick; Albert Greene; Timothy J Craig; Anne Kagey-Sobotka
Journal:  J Allergy Clin Immunol       Date:  2006-03       Impact factor: 10.793

Review 9.  Sublingual immunotherapy for allergic rhinitis.

Authors:  D R Wilson; L I Torres; S R Durham
Journal:  Cochrane Database Syst Rev       Date:  2003
  9 in total
  1 in total

1.  Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.

Authors:  C Barth; F Anero; O Pfaar; L Klimek; K Hörmann; B A Stuck
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-09       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.